J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A

Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.